Padcev

Indicated For

Locally advanced or metastatic urothelial cancer

About This Medication

# PADCEV Patient Connect Program Patient Guide: How to Get Padcev (enfortumab vedotin-ejfv) at Low or No Cost Padcev (enfortumab vedotin-ejfv) is a prescription medication used to treat certain types of advanced bladder cancer, known as locally advanced or metastatic urothelial carcinoma (la/mUC). The **PADCEV Patient Connect Program**, offered by Astellas Pharma and Pfizer through PADCEV Support Solutions, provides financial help to make Padcev more affordable, including a Copay Assistance Program for commercially insured patients and a Patient Assistance Program (PAP) for uninsured patients who qualify.[1][2] ## About Padcev and Who It's For **Padcev** is an antibody-drug conjugate that targets Nectin-4 on cancer cells, delivering a chemotherapy agent directly to tumors. It's approved for adults with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum chemotherapy, or who are cisplatin-ineligible and have had prior therapy. It can also be used with Keytruda (pembrolizumab) as an alternative to platinum chemotherapy in some cases.[5] This guide explains the PADCEV Patient Connect Program, which connects patients to two main assistance options: - **Copay Assistance Program**: Reduces out-of-pocket costs for eligible commercially insured patients. - **Patient Assistance Program (PAP)**: Provides Padcev at no cost to qualifying uninsured patients.[1][2] The program also offers **Patient Connect** support, linking you to third-party resources for emotional, logistical, and informational help, like counseling, transportation, or nutrition advice.[1][3] ## Who Qualifies? Eligibility varies by program: - **Copay Assistance Program**: - Must have **private commercial health insurance** (not government programs like Medicare, Medicaid, or VA). - **No income requirements**. - Covers up to **$25,000 per calendar year**, with patients paying **as little as $5 per dose**. - Enrollment lasts **12 months**.[2] - **Patient Assistance Program (PAP)**: - For **uninsured patients** who meet program requirements (specific income thresholds not detailed publicly; call for details).[1] - Padcev is provided **at no cost**.[1] Contact PADCEV Support Solutions at **1-888-402-0627** (Mon–Fri, 8:30 AM–8:00 PM ET) to check eligibility.[1][2] ## Income Eligibility Breakdown The Copay Program has **no income limits**, making it accessible to a wide range of commercially insured patients. For PAP, income guidelines apply but are not publicly specified—eligibility is assessed case-by-case for uninsured patients.[1][2] Here's a summary table: | Program | Insurance Type | Income Requirements | Max Annual Assistance | Patient Cost per Dose | |--------------------------|-------------------------|---------------------|-----------------------|-----------------------| | **Copay Assistance** | Commercial only | None | $25,000 | As low as $5 |[2] | **Patient Assistance** | Uninsured | Yes (details via phone) | Full cost of drug | $0 |[1] **Note**: Federal/state healthcare program patients (e.g., Medicare) are ineligible for Copay Assistance.[2] ## Insurance Requirements - **Commercial Insurance**: Eligible for Copay Program if not on government insurance. The program helps cover copays, coinsurance, or deductibles.[2] - **Uninsured**: Qualify for PAP if meeting other criteria.[1] - **Government Insurance (Medicare, Medicaid, etc.)**: Not eligible for Copay Program. Explore other options like Medicare Extra Help or state programs. Patient Connect may link to additional resources.[1][2] PADCEV Support Solutions can verify coverage and suggest alternatives.[1] ## Step-by-Step Application Process Your healthcare provider (HCP) plays a key role. Here's how to apply:[1][4][7] 1. **Discuss with Your HCP**: Ask about Padcev and PADCEV Support Solutions. They can start the process. 2. **Choose Enrollment Method** (3 options):[4] - **Fax**: HCP completes the **Patient Enrollment Form** (downloadable), signs it with you, and faxes to **1-877-747-6843**.[4][7] - **Online**: HCP logs into the Prescriber Portal to submit the form electronically.[4] - **Phone**: Call **1-888-402-0627** (Mon–Fri, 8:30 AM–8:00 PM ET) to enroll with help from a specialist.[1][4] 3. **Submit Required Info**: Includes patient details, HCP signature, prescription, and insurance info (if applicable). For PAP, additional eligibility proof may be needed.[1][7] 4. **Approval Notification**: If approved, you and your HCP are notified. For PAP, drug ships to HCP's office.[1] 5. **Access Support**: Enrolled patients get Patient Connect resources tailored to needs.[1] Call for help anytime—specialists guide you through.[1] ## Timeline and Delivery - **Processing**: Not specified; call for status updates. Approvals lead to quick notification.[1] - **Delivery**: For PAP, Padcev ships **directly to your HCP** (not home). Pick up from their office.[1] - **Copay Cards**: Issued digitally or by mail for immediate use at pharmacy.[2] Expect 1-2 weeks typically, but phone support expedites.[1][4] ## Alternatives if Denied or Ineligible - **Switch Programs**: If denied Copay, check PAP (if uninsured).[1] - **Patient Connect**: Get referrals to independent organizations for financial aid, transportation, or emotional support.[1][3] - **Other Resources**: - PAN Foundation or CancerCare grants. - State pharmaceutical assistance programs. - Medicare Savings Programs (if applicable).[2] - **Generic/Biosimilar**: None available for Padcev.[5] - **Contact Support**: Call **1-888-402-0627** for personalized options.[1] ## Reauthorization and Refills Copay enrollment lasts **12 months**; reapply annually. PAP may require periodic HCP confirmation. Your HCP handles refills via the portal or phone.[2][4] ## Important Disclaimer This guide is for informational purposes based on publicly available data as of 2024. Program details can change; always verify with PADCEV Support Solutions at 1-888-402-0627 or PADCEVSupportSolutions.com. Not all patients qualify. PADCEV has serious side effects (see full Prescribing Information, including Boxed Warning). Consult your HCP. Astellas/Pfizer reserve rights to modify/terminate programs. Support via Patient Connect is through independent third parties, not guaranteed.[1][2][7]

Program information last verified: March 30, 2026